Pharma Partnerships
A key piece of OSE Immunotherapeutics business model
For OSE Immunotherapeutics, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE Immunotherapeutics business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates.
OSE Immunotherapeutics is actively pursuing a partnership strategy with potential pharmaceutical partners.
Existing partnerships signed with premier international pharmaceutical companies for the clinical development of the Company’s most advanced and innovative programs include the following:
– Reflecting an amendment of the existing collaboration and license agreement for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371, which are being investigated in Phase I clinical studies in advanced solid tumors, development will now also be pursued in cardiovascular-renal-metabolic (CRM) diseases.
– A new preclinical program will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting anti-PD1/cytokine platform via an asset acquisition.
Each of these agreements includes an initial upfront payment as well as milestone payments and royalties on potential future sales.
Together, existing partnerships represent a potential of up to €2.1 billion of revenue for OSE Immunotherapeutics and additional royalties on future sales, demonstrating our expertise discovering valuable new targets and therapies and validating the high potential of our drug candidates.